Incarcerated Obturator Hernia in a Scoliotic Patient: A Case Report and Review of Literature
DOI:
https://doi.org/10.38179/ijcr.v4i1.267Keywords:
Incarcerated obturator hernia, Case report, Laparoscopic vs open treatment, Hernioplasty vs herniorrhaphy, Small bowel obstruction, Emaciated scoliotic female patientAbstract
Background: Obturator hernia is a rare entity mainly occurring in cachectic females, which usually end in intestinal obstruction leading to drastic situations due to diagnostic challenges.
Case Report: A case of a low Body mass index scoliotic female patient presented with signs of intestinal occlusion, with no other pertinent findings on physical exam. Computed tomography scan has demonstrated an incarcerated right obturator hernia with no intestinal suffering. Laparoscopic exploration has confirmed the diagnosis, but due to uneasy reduction of the incarcerated small bowel loop, an open reduction and hernioplasty was performed, leading to an uneventful postoperative hospital stay and home discharge.
Discussion: Anatomically, the obturator foramen is a large aperture formed by the ischium and the pubis. It is oval in males, while triangular and wider in females, leading to a 9 times higher incidence in females. More than 90% of cases present with mechanical intestinal obstruction, manifesting as nausea, vomiting, and a crampy intermittent acute abdominal pain. The sac content is mostly small bowel, but cases of ovaries, Meckel’s diverticulum, appendix, fallopian tube, omentum, and colon have been observed and stated in literature.
Conclusion: Obturator hernia is associated with higher mortality rates than other abdominal hernias, hence prompt diagnosis is required, where computed tomography scan is the gold standard. Laparoscopic technique have many advantages, while it is not suitable in septic or unstable conditions. Hernioplasty is superior to herniorrhaphy in clean surgeries.
References
Nakhla AM, Rosner W. Stimulation of prostate cancer growth by androgens and estrogens through the intermediacy of sex hormone-binding globulin. Endocrinology. 1996;137(10):4126-4129. PMID: 8828467. https://doi.org/10.1210/endo.137.10.8828467
Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR; Baltimore Longitudinal Study of Aging. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab. 2001;86(2):724-731. PMID: 11158037. https://doi.org/10.1210/jcem.86.2.7219
Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin. 1972;22(4):232-240. PMID: 4625049. https://doi.org/10.3322/canjclin.22.4.232
Morgentaler A, Bruning CO 3rd, DeWolf WC. Occult prostate cancer in men with low serum testosterone levels. JAMA. 1996;276(23):1904-1906. PMID: 8968017.
Hsing AW, Comstock GW. Serological precursors of cancer: serum hormones and risk of subsequent prostate cancer. Cancer Epidemiol Biomarkers Prev. 1993;2(1):27-32. PMID: 8420607.
Morgentaler A, Rhoden EL. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less. Urology. 2006;68(6):1263-1267. PMID: 17169647. https://doi.org/10.1016/j.urology.2006.08.1058
Mikkola AK, Aro JL, Rannikko SA, Salo JO. Pretreatment plasma testosterone and estradiol levels in patients with locally advanced or metastasized prostatic cancer. FINNPROSTATE Group. Prostate. 1999;39(3):175-181. PMID: 10334106. https://doi.org/10.1002/(sici)1097-0045(19990515)39:3%3C175::aid-pros5%3E3.0.co;2-e
Gann PH, Hennekens CH, Ma J, Longcope C, Stampfer MJ. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst. 1996;88(16):1118-1126. PMID: 8757191. https://doi.org/10.1093/jnci/88.16.1118
Mohr BA, Feldman HA, Kalish LA, Longcope C, McKinlay JB. Are serum hormones associated with the risk of prostate cancer? Prospective results from the Massachusetts Male Aging Study. Urology. 2001;57(5):930-935. PMID: 11337297. https://doi.org/10.1016/s0090-4295(00)01116-x
Sher DJ, Mantzoros C, Jacobus S, Regan MM, Lee GS, Oh WK. Absence of relationship between steroid hormone levels and prostate cancer tumor grade. Urology. 2009;73(2):356-362. PMID: 19036418. https://doi.org/10.1016/j.urology.2008.07.068
Yamamoto S, Yonese J, Kawakami S, et al. Preoperative serum testosterone level as an independent predictor of treatment failure following radical prostatectomy. Eur Urol. 2007;52(3):696-701. PMID: 17412490. https://doi.org/10.1016/j.eururo.2007.03.052
Hoffman MA, DeWolf WC, Morgentaler A. Is low serum free testosterone a marker for high grade prostate cancer? J Urol. 2000 Mar;163(3):824-7. PMID: 10687985.
Massengill JC, Sun L, Moul JW, Wu H, McLeod DG, Amling C, Lance R, Foley J, Sexton W, Kusuda L, Chung A, Soderdahl D, Donahue T. Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol. 2003 May;169(5):1670-5. PMID: 12686805. https://doi.org/10.1097/01.ju.0000062674.43964.d0
Teloken C, Da Ros CT, Caraver F, Weber FA, Cavalheiro AP, Graziottin TM. Low serum testosterone levels are associated with positive surgical margins in radical retropubic prostatectomy: hypogonadism represents bad prognosis in prostate cancer. J Urol. 2005 Dec;174(6):2178-80. PMID: 16280759. https://doi.org/10.1097/01.ju.0000181818.51977.29
Arunprasad K, Chandramohan. Association between low serum testosterone and prostate cancer behaviour. International Journal of Contemporary Medical Research. 2018;5(8):H1-H4. http://dx.doi.org/10.21276/ijcmr.2018.5.8.3
Jarow JP, Troiani J, McNellis D, Wiederhorn R, Fang G, Handelsman H. Use of biomarkers to assess tissue specific androgen adequacy: defining male hypogonadism. J Urol. 2013 Feb;189(2):633-7. PMID: 23260553. https://doi.org/10.1016/j.juro.2012.09.025
Iwamoto T, Yanase T, Koh E, Horie H, Baba K, Namiki M, Nawata H. [Reference ranges of total serum and free testosterone in Japanese male adults]. Nihon Hinyokika Gakkai Zasshi. 2004 Sep;95(6):751-60. Japanese. PMID: 15508699. https://doi.org/10.5980/jpnjurol1989.95.751
Mearini L, Zucchi A, Nunzi E, Villirillo T, Bini V, Porena M. Low serum testosterone levels are predictive of prostate cancer. World J Urol. 2013 Apr;31(2):247-52. PMID: 22068548. https://doi.org/10.1007/s00345-011-0793-x
Song W, Khera M. Physiological normal levels of androgen inhibit proliferation of prostate cancer cells in vitro. Asian J Androl. 2014 Nov-Dec;16(6):864-8. PMID: 24923459. https://doi.org/10.4103/1008-682x.129132
Miller LR, Partin AW, Chan DW, Bruzek DJ, Dobs AS, Epstein JI, Walsh PC. Influence of radical prostatectomy on serum hormone levels. J Urol. 1998 Aug;160(2):449-53. PMID: 9679896
Zhang PL, Rosen S, Veeramachaneni R, Kao J, DeWolf WC, Bubley G. Association between prostate cancer and serum testosterone levels. Prostate. 2002 Nov 1;53(3):179-82. PMID: 12386917. https://doi.org/10.1002/pros.10140
Pierorazio PM, Ferrucci L, Kettermann A, Longo DL, Metter EJ, Carter HB. Serum testosterone is associated with aggressive prostate cancer in older men: results from the Baltimore Longitudinal Study of Aging. BJU Int. 2010 Mar;105(6):824-9. PMID: 19751256. https://doi.org/10.1111/j.1464-410x.2009.08853.x
Márquez MP, García-Cruz E, Bartolomé MP, Ciudin A, Pérez JH, Caparrós MR, Asensio AA. Low testosterone levels are associated with poor prognosis risk factors on needle prostate cancer biopsies: 97. Journal of Men's Health. 2009 Sep;6(3):252-. https://doi.org/10.1016/j.jomh.2009.08.095
Schatzl G, Madersbacher S, Thurridl T, Waldmüller J, Kramer G, Haitel A, Marberger M. High-grade prostate cancer is associated with low serum testosterone levels. Prostate. 2001 Apr;47(1):52-8. PMID: 11304729. https://doi.org/10.1002/pros.1046
Schatzl G, Madersbacher S, Haitel A, Gsur A, Preyer M, Haidinger G, Gassner C, Ochsner M, Marberger M. Associations of serum testosterone with microvessel density, androgen receptor density and androgen receptor gene polymorphism in prostate cancer. J Urol. 2003 Apr;169(4):1312-5. PMID: 12629350. https://doi.org/10.1097/01.ju.0000056900.26628.16
Shaneyfelt T, Husein R, Bubley G, Mantzoros CS. Hormonal predictors of prostate cancer: a meta-analysis. J Clin Oncol. 2000 Feb;18(4):847-53. PMID: 10673527. https://doi.org/10.1200/jco.2000.18.4.847
Yano M, Imamoto T, Suzuki H, Fukasawa S, Kojima S, Komiya A, Naya Y, Ichikawa T. The clinical potential of pretreatment serum testosterone level to improve the efficiency of prostate cancer screening. Eur Urol. 2007 Feb;51(2):375-80. PMID: 17005316. https://doi.org/10.1016/j.eururo.2006.08.047
Endogenous Hormones and Prostate Cancer Collaborative Group, Roddam AW, Allen NE, Appleby P, Key TJ. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst. 2008 Feb 6;100(3):170-83. PMID: 18230794. https://doi.org/10.1093/jnci/djm323
Muller RL, Gerber L, Moreira DM, Andriole G, Castro-Santamaria R, Freedland SJ. Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the Reduction by Dutasteride of Prostate Cancer Events trial. Eur Urol. 2012 Nov;62(5):757-64. PMID: 22658758. https://doi.org/10.1016/j.eururo.2012.05.025

Published
How to Cite
Issue
Section
Copyright (c) 2024 International Journal of Clinical Research

This work is licensed under a Creative Commons Attribution 4.0 International License.